Nacuity Pharmaceuticals
Nacuity Pharmaceuticals is conducting the SLO-RP Study Phase 1/2 clinical trial of their proprietary NPI-001 Tablets, an antioxidant drug. The study will examine the safety and efficacy of these oral NPI-001 Tablets compared to placebo tablets for participants who have vision loss due to retinitis pigmentosa (RP) with Usher syndrome. The study takes place over the course of 24 months. This study is expected to be completed in late 2025.
Nacuity Pharmaceuticals Info Page
Link to study details on ClinicalTrials.gov
Nacuity Related Science News
Nacuity Pharmaceuticals, Inc. announced that its investigative therapy, NPI-001, for treating retinitis pigmentosa (RP), has received both Fast Track Designation and Orphan Drug Designation from the U.S. FDA.
In June 2023, Nacuity announced they completed enrollment in the SLO-RP Phase I/II clinical trial of NPI-001 tablets.
